RT Journal Article
SR Electronic
T1 The age and sex distribution of COVID-19 cases and fatalities in India
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.14.20153957
DO 10.1101/2020.07.14.20153957
A1 Gupta, Sourendu
YR 2020
UL http://medrxiv.org/content/early/2020/07/16/2020.07.14.20153957.abstract
AB Using anonymous publicly available data on COVID-19 infections and gross outcomes in India, the age and sex distribution of infections and fatalities is studied. The age structure in the count of infections is not proportional to that in the population, indicating the role of either co-morbidity or differential attack rate. There is a strong age structure in the sex ratio of cases, with the female to male ratio being about 50% on average. The ratio drops between puberty and menopause. No such structure is visible in the sex ratio of fatalities. The overall age distribution of fatalities is consistent with a model which uses the empirical age structure of infections and a previous determinations of age structured IFR. The average IFR for India is then expected to be 0.4% with a 95% CrI in [0.22%, 0.77%].Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was used for this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Only publicly available anonymized data sets were used. No approval was required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study only used publicly available data. https://api.covid19india.org/